Montiva
Generic Name
Montelukast
Manufacturer
Beximco Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| montiva 5 mg flash tablet | ৳ 9.00 | ৳ 90.00 |
Description
Overview of the medicine
Montiva 5 mg Flash Tablet contains Montelukast, a leukotriene receptor antagonist, used for the prevention and chronic treatment of asthma and for the relief of symptoms of seasonal and perennial allergic rhinitis. The flash tablet formulation allows it to dissolve rapidly in the mouth without water, making it suitable for children and patients who have difficulty swallowing traditional tablets.
Uses & Indications
Dosage
Adults
The usual dosage for adults (15 years and older) is 10 mg once daily in the evening. This 5 mg tablet is primarily intended for children 6-14 years of age.
Elderly
No dosage adjustment is generally required for elderly patients.
Renal_impairment
No dosage adjustment is required for patients with renal impairment.
Hepatic_impairment
No dosage adjustment is required for patients with mild to moderate hepatic impairment. Data for severe hepatic impairment are not available.
Children_6_14_years
5 mg once daily in the evening. Take Montiva 5 mg Flash Tablet orally, dissolving it on the tongue.
How to Take
Montiva 5 mg Flash Tablet should be taken once daily in the evening, with or without food. Place the flash tablet on the tongue and allow it to disintegrate completely before swallowing. No water is needed.
Mechanism of Action
Montelukast selectively binds to and blocks the cysteinyl leukotriene 1 (CysLT1) receptor, preventing the action of leukotrienes (LTC4, LTD4, LTE4). Leukotrienes are potent inflammatory mediators released from various cells, including mast cells and eosinophils, and are associated with the pathophysiology of asthma and allergic rhinitis. By inhibiting these effects, montelukast improves asthma control, reduces airway inflammation, and alleviates allergic rhinitis symptoms.
Pharmacokinetics
Onset
Clinical improvement in asthma symptoms typically occurs within 1 day of starting therapy.
Excretion
Primarily excreted in feces (approximately 86%) via bile; less than 0.2% is excreted in urine. Renal excretion is negligible.
Half life
Plasma half-life ranges from 2.7 to 5.5 hours in healthy young adults.
Absorption
Rapidly absorbed after oral administration. Mean peak plasma concentration (Cmax) is achieved in approximately 2-4 hours for the 5 mg dose. Oral bioavailability is about 64%.
Metabolism
Extensively metabolized by cytochrome P450 enzymes, particularly CYP3A4, CYP2C8, and CYP2C9.
Side Effects
Contraindications
- Hypersensitivity to montelukast or any of its excipients.
- Not indicated for the relief of acute asthma attacks (status asthmaticus).
Drug Interactions
Rifampicin
May decrease the plasma concentration of montelukast, potentially reducing its efficacy. Monitor clinical response.
Phenobarbital
May decrease the area under the plasma concentration-time curve (AUC) of montelukast by approximately 40%.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
In post-marketing experience, there have been reports of acute overdose. The most frequently occurring adverse events were abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. There is no specific antidote; treatment is symptomatic and supportive.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have not shown harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. Montelukast is excreted in human milk; caution should be exercised when administered to a nursing woman.
Side Effects
Contraindications
- Hypersensitivity to montelukast or any of its excipients.
- Not indicated for the relief of acute asthma attacks (status asthmaticus).
Drug Interactions
Rifampicin
May decrease the plasma concentration of montelukast, potentially reducing its efficacy. Monitor clinical response.
Phenobarbital
May decrease the area under the plasma concentration-time curve (AUC) of montelukast by approximately 40%.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
In post-marketing experience, there have been reports of acute overdose. The most frequently occurring adverse events were abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. There is no specific antidote; treatment is symptomatic and supportive.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have not shown harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. Montelukast is excreted in human milk; caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months from the date of manufacture. Refer to the packaging for the exact expiry date.
Availability
Available in pharmacies nationwide
Approval Status
Approved by regulatory authorities (e.g., FDA, DGDA)
Patent Status
Generic versions available
Clinical Trials
Montelukast has been extensively studied in numerous clinical trials demonstrating its efficacy and safety in the treatment of asthma and allergic rhinitis across various age groups. Key trials have shown significant improvements in lung function, symptom control, and quality of life.
Lab Monitoring
- Routine laboratory monitoring is generally not required.
- Monitor liver function tests periodically in patients with pre-existing hepatic impairment or if symptoms of liver dysfunction appear.
Doctor Notes
- Counsel patients and caregivers about potential neuropsychiatric events and to report any changes immediately.
- Emphasize that montelukast is not for acute attacks and patients should always have a rescue inhaler.
- Assess adherence, as irregular use can lead to suboptimal asthma/rhinitis control.
Patient Guidelines
- Take Montiva regularly every evening, even if you feel well.
- Do not use this medicine for acute asthma attacks; use your rescue inhaler as prescribed.
- Inform your doctor if your asthma symptoms worsen or if you experience any neuropsychiatric symptoms.
- Do not stop taking other asthma medications unless advised by your doctor.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Montiva generally does not impair the ability to drive or operate machinery. However, some individuals may experience dizziness or drowsiness. If you experience these side effects, avoid driving or operating machinery.
Lifestyle Advice
- Avoid known asthma triggers and allergens.
- Maintain a healthy lifestyle, including regular exercise (if appropriate) and a balanced diet.
- Quit smoking and avoid exposure to secondhand smoke.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Montiva Brand
Other medicines available under the same brand name
